ロード中...
Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro
BACKGROUND: Everolimus (EVE), a mammalian target of rapamycin inhibitor, has been proposed as liver transplant immunosuppressive drug, gaining wide interest also for the treatment of cancer. Although an appropriate tolerance, it may induce several adverse effects, such as fibro-interstitial pneumoni...
保存先:
| 出版年: | BMC Gastroenterol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570634/ https://ncbi.nlm.nih.gov/pubmed/26369804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0347-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|